Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092467 · ClinicalTrials.gov registry record · Phase 4
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
A Phase 4 study of Arthritis, Rheumatoid, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 4,372
- Enrollment target
- 20
- Study locations
NCT02092467 is a Phase 4 study of Arthritis, Rheumatoid that has completed, run by Pfizer. The registered enrollment target is 4,372 participants, above the 479-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (813% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT02092467, a Phase 4 study of Arthritis, Rheumatoid, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4,372 participants
- Enrollment target
- 20
- Study locations
Study Summary
This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.
Conditions Studied
Interventions
- DRUG tofacitinib
- BIOLOGICAL adalimumab
- BIOLOGICAL etanercept
Study Locations (20)
California
- Medvin Clinical Research - Covina
- Med Investigations, Inc. - Fair Oaks
- Talbert Medical Group - Huntington Beach
- University of California, San Diego (UCSD)- Perlman Ambulatory Clinic - La Jolla
- Valerius Medical Group And Research Center Of Greater Long Beach, Inc. - Long Beach
- ProHealth Partners - Long Beach
- Keck Medicine of USC - Los Angeles
- California Medical Research Associates Inc - Northridge
- Desert Medical Advances - Palm Desert
- Medvin Clinical Research - Placentia
- Sierra Rheumatology, Inc. - Roseville
- San Diego Arthritis Medical Clinic - San Diego
- Dr. Orrin M. Troum, Md And Medical Associates - Santa Monica
Alabama
- University of Alabama at Birmingham (UAB), Arthritis Clinical Intervention Program - Birmingham
- Rheumatology Associates of North Alabama, PC - Huntsville
- Clinical and Translational Research Center of Alabama, PC - Tuscaloosa
Arizona
- Southern Arizona VA Health Care System (SAVAHCS) - Tucson
- University of Arizona Clinical and Translational Science Research Center - Tucson
Arkansas
- CHI St. Vincent Medical Group Hot Springs - Hot Springs
- Arthritis And Rheumatism Associates LLC - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,372 participants |
| Start Date | 2014-03-14 |
| Est. Completion | 2020-07-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02092467
The ClinicalTrials.gov registry entry for NCT02092467 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4,372 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 479-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (813% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 3 interventions - of which tofacitinib is the first listed.
NCT02092467 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT02092467 about?
NCT02092467 is a clinical study titled "Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis". This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin...
What is the current status of trial NCT02092467?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4,372 participants. The study started on 2014-03-14. Estimated completion is 2020-07-22.
What conditions does trial NCT02092467 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT02092467?
The interventions under investigation include: tofacitinib (DRUG), adalimumab (BIOLOGICAL), etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT02092467?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02092467 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chronic Pain in Rheumatoid Arthritis
RECRUITING
-
R-2487 in Patients With Rheumatoid Arthritis
RECRUITING · Phase 1
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
RECRUITING · Phase 2
-
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
RECRUITING
-
INFINITY™ With ADAPTIS™ Technology Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.